Table 2.
The distribution of comorbidities in the study cohort according to ICD-10.
| Characteristic | All Patients, N = 799 | QT ÷ Risk (N = 316) | QT + Risk (N = 483) | p-Value 1 |
|---|---|---|---|---|
| Affective disorder, n (%) | 180 (23) | 85 (27) | 95 (20) | 0.017 |
| Cancer, n (%) | 17 (2.1) | 13 (4.1) | 4 (0.8) | 0.002 |
| Cardiovascular comorbidity, n (%) | 125 (16) | 63 (20) | 62 (13) | 0.007 |
| Diabetes, n (%) | 48 (6.0) | 26 (8.2) | 22 (4.6) | 0.033 |
| Nephrological disease, n (%) | 9 (1.1) | 5 (1.6) | 4 (0.8) | 0.33 |
| Pacemaker, n (%) | 10 (1.3) | 6 (1.9) | 4 (0.8) | 0.21 |
| Thyroid disease, n (%) | 29 (3.6) | 15 (4.7) | 14 (2.9) | 0.17 |
| Psychotic disorder, n (%) | 188 (24) | 53 (17) | 135 (28) | <0.001 |
| 2 ADHD, n (%) | 29 (3.6) | 10 (3.2) | 19 (3.9) | 0.57 |
| Anxiety, n (%) | 56 (7.0) | 35 (11) | 21 (4.3) | <0.001 |
| Total number of diseases, Median (IQR) | 2 (1–3) | 2 (1–4) | 2 (2–3) | 0.43 |
| Unknown | 320 | 121 | 199 |
1 Pearson’s Chi-squared test; Fisher’s exact test; Wilcoxon rank sum test. 2 Attention-Deficit/Hyperactivity Disorder.